BSX vs STRO · P/E 20, rev $16.75B vs rev $62.0M
Boston Scientific Corp (BSX) versus Sutro Biopharma (STRO) — a side-by-side from cached financials, not a winner call.
Boston Scientific Corp (BSX) is a medical devices company listed on US.
Sutro Biopharma (STRO) is a biotechnology company listed on NASDAQ.
Latest reported BSX revenue for 2024-12-31 was $16.75B. Net income was $1.85B. Revenue was up 17.6% from 2023-12-31 to 2024-12-31. BSX currently screens at market cap $71.81B and trailing P/E 20.2.
Latest reported STRO revenue for 2024-12-31 was $62.0M. Net income was -$227.5M. Revenue was down 59.6% from 2023-12-31 to 2024-12-31. STRO currently screens at market cap $470.8M.
BSX currently screens at market cap $71.81B and trailing P/E 20.2. STRO currently screens at market cap $470.8M.
Not investment advice. Open the BSX and STRO stock pages for the full models.
Not investment advice.